Journal of Substance Abuse Treatment
Volume 39, Issue 2 , Pages 96-104 , September 2010

Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians

  • Cynthia L. Arfken, Ph.D.

      Affiliations

    • Department of Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI 48207, USA
    • Corresponding Author InformationCorresponding author. Department of Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI 48207, USA. Tel.: +1 313 993 3490; fax: +1 313 577 5062.
    • ,
  • Chris-Ellyn Johanson, Ph.D.

      Affiliations

    • Department of Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI 48207, USA
    • CRS Associates, LLC, Chicago, IL 60616, USA
    • ,
  • Salvatore di Menza, M.S.

      Affiliations

    • CRS Associates, LLC, Chicago, IL 60616, USA
    • ,
  • Charles Roberts Schuster, Ph.D.

      Affiliations

    • Department of Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI 48207, USA
    • CRS Associates, LLC, Chicago, IL 60616, USA

Received 13 January 2010 ,Revised 19 April 2010 ,Accepted 5 May 2010.

References 

  1. Asch DA, Jedrziewski MK, Christakis NA. Response rates to mail surveys published in medical journals. Journal of Clinical Epidemiology. 1997;50:1129–1136
  2. Barry DT, Irwin KS, Jones ES, Becker WC, et al. Integrating buprenorphine treatment into office-based practice: A qualitative study. Journal of General Medicine. 2008;24:218–225
  3. Fiellin DA, O'Connor PG. Clinical practice. Office-based treatment of opioid-dependent patients. New England Journal of Medicine. 2002;347:817–823
  4. Fiellin DA, Pantalon MV, Chawarski MC, Moore BA, et al. Counseling plus buprenophine–naloxone maintenance therapy for opioid dependence. New England Journal of Medicine. 2006;355:365–374
  5. Fudula PJ, Bridge TP, Herber S, Williford WO, et al. Office-based treatment of opiate addiction with a sublingual-table of buprenorphine and naloxone. New England Journal of Medicine. 2003;349:949–958
  6. Gunderson EW, Fiellin DA, Levin FR, Sullivan LE, et al. Evaluation of a combined online and in person training in the use of buprenorphine. Substance Abuse. 2006;27:39–45
  7. Harper I. Temgesic abuse. New Zealand Medical Journal. 1983;96:777
  8. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. Journal of the American Medical Association. 1992;267:2750–2755
  9. Kresina TF, Litwin A, Marion I, Lubran R, Clark HW. United States government oversight and regulation of medication assisted treatment for the treatment of opioid dependence. Journal of Drug Policy Analysis. 2009;2:1–23
  10. Lavelle TL, Hammersley R, Forsyth A, Bain D. The use of buprenorphine and temazepam by drug injectors. Journal of Addictive Diseases. 1991;10:5–14
  11. Ling W, Charuvastra C, Collins JF, Batki S, et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial. Addiction. 1998;93:475–486
  12. Mark TL, Kassed CA, Vandivort-Warren R, Levit KR, et al. Alcohol and opioid dependence medications: Prescription trends, overall and by physician specialty. Drug and Alcohol Dependence. 2009;99:345–349
  13. McNicholas L. SAMHSA clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol. 2004;40
  14. Mello NK, Mendelson JH. Behavioral pharmacology of buprenorphine. Drug and Alcohol Dependence. 1985;14:283–303
  15. Netherland J, Botsko M, Egan JE, Saxon AJ, et al. Factors affecting willingness to provide buprenorphine treatment. Journal of Substance Abuse Treatment. 2009;36:244–251
  16. O'Connor JJ, Maloney E, Travers R, Campbell A. Buprenorphine abuse among opiate addicts. British Journal of Addiction. 1988;83:1083–1087
  17. Rogers EV. Diffusion of innovations. 5th ed.. New York: Free Press; 2003;
  18. SAMHSA . DASIS report: Heroin—Changes in how it is used, 1995–2005. 2007;
  19. SAMHSA . DASIS report: Non-heroin opiate admissions, 2003. 2006;
  20. Singh RA, Mattoo SK, Malhotra A, Varma VK. Cases of buprenorphine abuse in India. Acta Psychiatrica Scandinavica. 1992;86:46–48
  21. Stanton A, McLeod C, Kissin W, Sonnefeld J, et al. Evaluation of the buprenorphine waiver program. In: Present to the College on Problems of Drug Dependence. 2005;
  22. Thomas CP, Reif S, Haq S, Wallack SS, et al. Use of buprenorphine for addiction treatment: Perspectives of addiction specialists and general psychiatrists. Psychiatric Services. 2008;59:909–916
  23. Walley AY, Alperen JK, Cheng DM, Botticelli M, et al. Office-based management of opioid dependence with buprenorphine: Clinical practices and barriers. Journal of General Medicine. 2008;23:1393–1398
  24. Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: Extrapolating from the laboratory to the clinic. Drug and Alcohol Dependence. 2003;70:S13–S27

PII: S0740-5472(10)00098-X

doi: 10.1016/j.jsat.2010.05.004

Journal of Substance Abuse Treatment
Volume 39, Issue 2 , Pages 96-104 , September 2010

Article Tools

* Image Usage & Resolution